Navigation Links
AxoGen, Inc. to Sponsor Surgeon Education Programs on Peripheral Nerve Surgery at American Society for Surgery of the Hand 2013
Date:10/1/2013

Alachua, FL (PRWEB) October 01, 2013

AxoGen, Inc. (NASDAQ: AXGN), a leader in the science and commercialization of surgical solutions for peripheral nerve repair, today announced that it will sponsor two educational forums at the American Society for Surgery of the Hand (ASSH) 2013 Meeting, taking place October 3-6 in San Francisco.

Karen Zaderej, Chief Executive Officer for AxoGen commented, “AxoGen is committed to providing opportunities for education on the latest science and research aimed at improving outcomes for peripheral nerve repair. We believe that evidence based discussions and hands on labs are valuable educational forums for the surgical community. AxoGen is pleased to make these sessions available to the ASSH membership.”

Educational events sponsored by AxoGen at ASSH 2013 include:

Hands-On Lab and Workshop: Application of Regenerative Medicine Technologies for Nerve Injuries (ASSH Forum 17)
Faculty: Peter Evans MD, PhD, FRSCS and Jeffrey Greenberg MD
Thursday, October 3; 6:30 - 8:00 p.m.

Panel Presentation: Redefining Our Expectations for Peripheral Nerve Repair: An Evidenced Based Approach (ASSH Forum 21)
Moderator: Ivica Ducic MD, PhD
Panelists: Peter Evans MD, PhD, Bauback Safa MD, MBA, FACS, Erick DeVinney, BS, Director of Clinical and Translational Sciences
Friday, October 4; 7:00 - 8:00 a.m.

In addition to sponsoring educational forums, AxoGen will be exhibiting its full portfolio of nerve repair and protection technologies and products at Booth 725 at the ASSH meeting.

About AxoGen, Inc.
AxoGen (NASDAQ: AXGN) is a leading regenerative medicine company dedicated to advancing the science and commercialization of peripheral nerve repair solutions. The Company’s innovative approach to regenerative medicine has resulted in first-in-class products that will define their product categories. AxoGen’s products offer a full suite of surgical nerve repair solutions including Avance® Nerve Graft, the only off-the-shelf commercially available processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site, AxoGuard® Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves, and AxoGuard® Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments.

AxoGen is the parent of its wholly owned operating subsidiary, AxoGen Corporation. AxoGen’s principal executive office and operations are located in Alachua, FL. For more information on AxoGen and its technology, please visit http://www.AxoGenInc.com. To receive email alerts directly from AxoGen, please click here http://www.axogeninc.com/emailalerts.html.

Cautionary Statements Concerning Forward-Looking Statements
This Press Release contains “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations or predictions of future conditions, events or results based on various assumptions and management’s estimates of trends and economic factors in the markets in which we are active, as well as our business plans. Words such as “expects”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates”, “projects”, “forecasts”, “continue”, “may”, “should”, “will” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements may include, without limitation, statements regarding product commercialization and marketing efforts for its portfolio of peripheral nerve repair products, Avance® Nerve Graft, AxoGuard® Nerve Connector and AxoGuard® Nerve Protector, product development, financial performance, sales growth, product adoption, market awareness of our products, data validation and our ability to maintain the listing of our common stock on a national securities exchange. The forward-looking statements are subject to risks and uncertainties, which may cause results to differ materially from those set forth in the statements. Forward-looking statements in this release should be evaluated together with the many uncertainties that affect AxoGen’s business and its market, particularly those discussed in the risk factors and cautionary statements in AxoGen’s filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and actual results may differ materially from those projected. The forward-looking statements are representative only as of the date they are made, and AxoGen assumes no responsibility to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offer, if at all, will be made only by means of the registration statement and the final prospectus.

Read the full story at http://www.prweb.com/releases/2013/10/prweb11180769.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. AxoGen, Inc. Announces Exercise of Over-Allotment Option
2. AxoGen, Inc. Closes $18 Million Offering and Moves to NASDAQ
3. AxoGen, Inc. Announces Pricing of $18 Million Underwritten Offering and Uplisting to NASDAQ
4. AxoGen, Inc. to Present at the Wedbush 2013 Life Sciences Management Access Conference
5. AxoGen, Inc. Reports Second Quarter 2013 Financial Results
6. AxoGen, Inc. Announces Presentation of Avance® Nerve Graft Data at the 18th Federation of European Societies for Surgery of the Hand Congress
7. AxoGen, Inc. Receives Grant in Partnership with Vanderbilt University from U.S. Department of Defense
8. AxoGen, Inc. Files Form S-1 Registration Statement
9. AxoGen, Inc. Announces CE Mark Approval for AxoGuard® Nerve Protector and AxoGuard® Nerve Connector
10. AxoGen, Inc. Announces Release Date of First Quarter 2013 Results and Conference Call
11. AxoGen, Inc. to Highlight Products at the American Academy of Orthopedic Surgeons 2013 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... January 17, 2017 , ... ... companies and ranked among the top US security companies for consecutive years, today ... This announcement brings a year-long independent board nomination process to a close and ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... ... Center and the Montclair State University’s Athletic Training Education program forged a relationship ... Athletic Training Education Program, which is consists of both student members and ...
(Date:1/16/2017)... ... ... California Southern University has named Dr. Steven Beazley University President. ... a core faculty member, teaching master’s and doctoral courses in the university’s School of ... where he earned his Doctor of Psychology degree in 1998. Dr. Beazley also has ...
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening Event planned for ... use by sports teams and the general public. Built in five months by Centerpoint, ... be converted into basketball or pickleball courts. The space is also suitable for indoor ...
(Date:1/16/2017)... ... January 16, 2017 , ... As New York’s ... Victor Giamos, MD to their medical staff, according to eye surgeon, Jeffrey Martin, ... Eye Care, a division of SightMD. Dr. Giamos will practice primarily out of ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... Calif. and KANSAS CITY, ... Children,s Hospitals Neonatal Consortium (CHNC) has selected Velos ... their visionary data management and multicenter initiatives. ... organization comprised of 32 Neonatal Intensive Care Units ... America . The consortium provides a benchmark ...
(Date:1/17/2017)... , Jan. 17, 2016  Attorney Advertising -- Bronstein, Gewirtz ... purchasers of Anthera Pharmaceuticals, Inc. ("Anthera" or the "Company") (NASDAQ: ... additional information and assist the investigation by visiting the firm,s ... Anthera and certain of its officers and/or directors have violated ... 1934. ...
(Date:1/17/2017)...   Tocagen Inc ., a clinical-stage, cancer-selective gene therapy company, ... research and pharmaceutical development at Tocagen, will present at Phacilitate ... 17-20 in Miami . Details ... ... replicating viruses - what to do when and why Date and ...
Breaking Medicine Technology: